CEMP Share Price

Open 7.30 Change Price %
High 7.40 1 Day -0.05 -0.68
Low 7.00 1 Week -0.20 -2.65
Close 7.35 1 Month 0.30 4.26
Volume 806345 1 Year -22.89 -75.69
52 Week High 32.31
52 Week Low 5.70
CEMP Important Levels
Resistance 2 7.72
Resistance 1 7.57
Pivot 7.25
Support 1 7.13
Support 2 6.98
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cempra, Inc. (NASDAQ: CEMP)

CEMP Technical Analysis 5
As on 8th Dec 2016 CEMP Share Price closed @ 7.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 18.01 & Strong Sell for SHORT-TERM with Stoploss of 15.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
CEMP Target for December
1st Target up-side 13.69
2nd Target up-side 18.74
3rd Target up-side 23.78
1st Target down-side -0.69
2nd Target down-side -5.74
3rd Target down-side -10.78
CEMP Other Details
Segment EQ
Market Capital 138632592.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cempra.com
CEMP Address
CEMP
6320 Quadrangle Drive
Suite 360
Chapel Hill, NC 27517
United States
Phone: 919-313-6601
Interactive Technical Analysis Chart Cempra, Inc. ( CEMP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cempra, Inc.
CEMP Business Profile
Cempra, Inc., formerly Cempra Holdings, LLC, incorporated on November 18, 2005, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Its program CEM-101 is developing in both oral and intravenous (IV), formulations initially for the treatment of community-acquired bacterial pneumonia (CABP). Its second program is Taksta, which is developing in the United States as an oral treatment for bacterial infections caused by Staphylococcus aureus (S. Aureus), including methicillin-resistant S. aureus (MRSA). As of January 30, 2012, the Company completed a Phase II clinical trial in, which the oral formulation of CEM-101 demonstrated comparable efficacy to the levofloxacin (commonly marketed as Levaquin). As of January 30, 2012, its second program Taksta has completed a Phase II clinical trial in patients with acute bacterial skin and skin structure infections (ABSSSI). CEM-101 is a macrolide. Macrolides are antimicrobial drugs that are active against aerobic and anaerobic gram-positive cocci and are prescribed for the treatment of respiratory tract and soft tissue infections. As of January 30, 2012, the Company is conducting a Phase I trial for the IV formulation of CEM-101. Taksta, the Company’s fusidic acid product candidate, is an oral antibiotic. Taksta is an oral dosing regimen of fusidic acid, which is an antibiotic. Fusidic acid is orally active against gram-positive bacteria, including all S. aureus strains such as HA-MRSA and CA-MRSA.